-
Je něco špatně v tomto záznamu ?
Pharmacological Foundations of Cannabis Chemovars
MA. Lewis, EB. Russo, KM. Smith,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
PubMed
29161743
DOI
10.1055/s-0043-122240
Knihovny.cz E-zdroje
- MeSH
- biologické markery metabolismus MeSH
- Cannabis genetika metabolismus MeSH
- kanabidiol metabolismus MeSH
- kanabinoidy biosyntéza farmakologie MeSH
- šlechtění rostlin MeSH
- tetrahydrokanabinol analogy a deriváty metabolismus MeSH
- Publikační typ
- časopisecké články MeSH
An advanced Mendelian Cannabis breeding program has been developed utilizing chemical markers to maximize the yield of phytocannabinoids and terpenoids with the aim to improve therapeutic efficacy and safety. Cannabis is often divided into several categories based on cannabinoid content. Type I, Δ9-tetrahydrocannabinol-predominant, is the prevalent offering in both medical and recreational marketplaces. In recent years, the therapeutic benefits of cannabidiol have been better recognized, leading to the promotion of additional chemovars: Type II, Cannabis that contains both Δ9-tetrahydrocannabinol and cannabidiol, and cannabidiol-predominant Type III Cannabis. While high-Δ9-tetrahydrocannabinol and high-myrcene chemovars dominate markets, these may not be optimal for patients who require distinct chemical profiles to achieve symptomatic relief. Type II Cannabis chemovars that display cannabidiol- and terpenoid-rich profiles have the potential to improve both efficacy and minimize adverse events associated with Δ9-tetrahydrocannabinol exposure. Cannabis samples were analyzed for cannabinoid and terpenoid content, and analytical results are presented via PhytoFacts, a patent-pending method of graphically displaying phytocannabinoid and terpenoid content, as well as scent, taste, and subjective therapeutic effect data. Examples from the breeding program are highlighted and include Type I, II, and III Cannabis chemovars, those highly potent in terpenoids in general, or single components, for example, limonene, pinene, terpinolene, and linalool. Additionally, it is demonstrated how Type I - III chemovars have been developed with conserved terpenoid proportions. Specific chemovars may produce enhanced analgesia, anti-inflammatory, anticonvulsant, antidepressant, and anti-anxiety effects, while simultaneously reducing sequelae of Δ9-tetrahydrocannabinol such as panic, toxic psychosis, and short-term memory impairment.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033539
- 003
- CZ-PrNML
- 005
- 20181015114056.0
- 007
- ta
- 008
- 181008s2018 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1055/s-0043-122240 $2 doi
- 035 __
- $a (PubMed)29161743
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Lewis, Mark A $u Napro Research, Westlake Village, CA, USA.
- 245 10
- $a Pharmacological Foundations of Cannabis Chemovars / $c MA. Lewis, EB. Russo, KM. Smith,
- 520 9_
- $a An advanced Mendelian Cannabis breeding program has been developed utilizing chemical markers to maximize the yield of phytocannabinoids and terpenoids with the aim to improve therapeutic efficacy and safety. Cannabis is often divided into several categories based on cannabinoid content. Type I, Δ9-tetrahydrocannabinol-predominant, is the prevalent offering in both medical and recreational marketplaces. In recent years, the therapeutic benefits of cannabidiol have been better recognized, leading to the promotion of additional chemovars: Type II, Cannabis that contains both Δ9-tetrahydrocannabinol and cannabidiol, and cannabidiol-predominant Type III Cannabis. While high-Δ9-tetrahydrocannabinol and high-myrcene chemovars dominate markets, these may not be optimal for patients who require distinct chemical profiles to achieve symptomatic relief. Type II Cannabis chemovars that display cannabidiol- and terpenoid-rich profiles have the potential to improve both efficacy and minimize adverse events associated with Δ9-tetrahydrocannabinol exposure. Cannabis samples were analyzed for cannabinoid and terpenoid content, and analytical results are presented via PhytoFacts, a patent-pending method of graphically displaying phytocannabinoid and terpenoid content, as well as scent, taste, and subjective therapeutic effect data. Examples from the breeding program are highlighted and include Type I, II, and III Cannabis chemovars, those highly potent in terpenoids in general, or single components, for example, limonene, pinene, terpinolene, and linalool. Additionally, it is demonstrated how Type I - III chemovars have been developed with conserved terpenoid proportions. Specific chemovars may produce enhanced analgesia, anti-inflammatory, anticonvulsant, antidepressant, and anti-anxiety effects, while simultaneously reducing sequelae of Δ9-tetrahydrocannabinol such as panic, toxic psychosis, and short-term memory impairment.
- 650 _2
- $a biologické markery $x metabolismus $7 D015415
- 650 _2
- $a kanabidiol $x metabolismus $7 D002185
- 650 _2
- $a kanabinoidy $x biosyntéza $x farmakologie $7 D002186
- 650 _2
- $a Cannabis $x genetika $x metabolismus $7 D002188
- 650 _2
- $a tetrahydrokanabinol $x analogy a deriváty $x metabolismus $7 D013759
- 650 _2
- $a šlechtění rostlin $7 D000069600
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Russo, Ethan B $u International Cannabis and Cannabinoids Institute, Prague, Czech Republic.
- 700 1_
- $a Smith, Kevin M $u Napro Research, Westlake Village, CA, USA.
- 773 0_
- $w MED00003839 $t Planta medica $x 1439-0221 $g Roč. 84, č. 4 (2018), s. 225-233
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29161743 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181015114553 $b ABA008
- 999 __
- $a ok $b bmc $g 1340196 $s 1030533
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 84 $c 4 $d 225-233 $e 20171121 $i 1439-0221 $m Planta medica $n Planta Med $x MED00003839
- LZP __
- $a Pubmed-20181008